Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone in Pediatric Participants With Friedreich's Ataxia
NCT06054893Phase 1Active, not recruiting
- Sponsor
- Biogen
- Start
- Jul 2024
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omaveloxolone in Friedreich ataxia (FA) (7 cohorts), sponsored by Biogen. Primary endpoints: Apparent Clearance at 96 hours, Maximum Concentration at 96 hours and 18 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT06054893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054893.